4//SEC Filing
Pivotal bioVenture Partners Fund I, L.P. 4
Accession 0000950170-23-038272
CIK 0001693011other
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 8:13 PM ET
Size
11.8 KB
Accession
0000950170-23-038272
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2023-08-01$4.80/sh+714,285$3,428,568→ 1,571,741 total(indirect: See footnotes) - Purchase
Common Stock
2023-08-01$4.80/sh+119,048$571,430→ 2,923,110 total(indirect: See footnotes)
Transactions
- Purchase
Common Stock
2023-08-01$4.80/sh+714,285$3,428,568→ 1,571,741 total(indirect: See footnotes) - Purchase
Common Stock
2023-08-01$4.80/sh+119,048$571,430→ 2,923,110 total(indirect: See footnotes)
Transactions
- Purchase
Common Stock
2023-08-01$4.80/sh+119,048$571,430→ 2,923,110 total(indirect: See footnotes) - Purchase
Common Stock
2023-08-01$4.80/sh+714,285$3,428,568→ 1,571,741 total(indirect: See footnotes)
Footnotes (4)
- [F1]Held directly by Pivotal bioVenture Partners Fund I, L.P ("Pivotal I").
- [F2]The general partner of Pivotal I and Pivotal bioVenture Partners Fund II, L.P ("Pivotal II") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL").
- [F3]The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
- [F4]Held by Pivotal II.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001695076
Filing Metadata
- Form type
- 4
- Filed
- Aug 2, 8:00 PM ET
- Accepted
- Aug 3, 8:13 PM ET
- Size
- 11.8 KB